MG
DFTX

Marex Group’s Definium Therapeutics DFTX Stock Holding History

Marex Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Sell
6,771
-13,229
-66% -$327K ﹤0.01% 839
2026
Q1 		$378K Hold
20,000
– – ﹤0.01% 701
2025
Q4 		$268K Buy
+20,000
New +$248K ﹤0.01% 738

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Marex Group's DFTX Position: Q2 2026 in Review

Marex Group reduced its Definium Therapeutics (DFTX) stake by 66% in Q2 2026, selling an estimated $327K and leaving 6,771 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Marex Group first reported a position in DFTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $378K in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Marex Group held 6,771 shares of Definium Therapeutics worth $319K as of Q2 2026.
  • Marex Group sold 13,229 Definium Therapeutics shares in Q2 2026, an estimated $327K.
  • Definium Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #839 holding.
  • Marex Group first reported a position in Definium Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Marex Group's Definium Therapeutics position peaked at $378K in Q1 2026.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.